Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141)

Chia Jui Yen, Naomi Kiyota, Nobuhiro Hanai, Shunji Takahashi, Tomoya Yokota, Shigemichi Iwae, Yasushi Shimizu, Ruey Long Hong, Masahiro Goto, Jin Hyoung Kang, Wing Sum Kenneth Li, Robert L. Ferris, Maura Gillison, Toshimitsu Endo, Vijayvel Jayaprakash, Makoto Tahara

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141)'. Together they form a unique fingerprint.

Medicine & Life Sciences